Nasdaq Falls Off Record Levels; Momenta, BioMarin Head in Opposite DirectionsThe Motley Fool • 08/19/20
BioMarin's stock falls 27% after FDA asks for additional data about experimental hemophilia A drugMarket Watch • 08/19/20
BioMarin Handed Setback By FDA On Hemophilia Drug; BMRN Stock PlungesInvestors Business Daily • 08/19/20
BioMarin Receives Complete Response Letter (CRL) from FDA for Valoctocogene Roxaparvovec Gene Therapy for Severe Hemophilia APRNewsWire • 08/19/20
BioMarin Pharmaceutical Inc.'s (BMRN) CEO Jean-Jacques Bienaimé on Q2 2020 Results - Earnings Call TranscriptSeeking Alpha • 08/05/20
BioMarin Pharmaceutical (BMRN) Q2 Earnings and Revenues Beat EstimatesZacks Investment Research • 08/04/20
BioMarin Announces Second Quarter 2020 Total Revenue Growth of 11% to $430 millionPRNewsWire • 08/04/20
Goldman Sachs Sees Big Gains From 7 Biotech & Pharma Conviction Buy Stocks24/7 Wall Street • 07/24/20
BioMarin to Host Second Quarter 2020 Financial Results Conference Call and Webcast on Tuesday, August 4 at 4:30pm ETPRNewsWire • 07/21/20
BioMarin Promotes Company Veteran, Brian R. Mueller, to Executive Vice President, CFOPRNewsWire • 06/29/20